Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.51 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.51 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.51 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.51 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.51 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.51 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticrynafen SCHEMBL30232637 | 1.00 | CYP2C9 (1.00) | CYP2C9ALDH1A1LMNANPSR1MAPT | |
| SCHEMBL13595454 | 0.90 | CYP2C9 (0.81) | CYP2C9ALDH1A1LMNANPSR1MAPT | |
| SCHEMBL11358120 | 0.88 | CYP2C9 (0.79) | CYP2C9ALDH1A1LMNANPSR1MAPT | |
| Ticrynafen SCHEMBL1708537 | 0.88 | CYP2C9 (0.78) | CYP2C9ALDH1A1LMNANPSR1MAPT | |
| Ticrynafen SCHEMBL11495557 | 0.85 | CYP2C9 (0.73) | CYP2C9ALDH1A1LMNANPSR1MAPT | |
| Ticrynafen SCHEMBL11495555 | 0.85 | CYP2C9 (0.73) | CYP2C9ALDH1A1LMNANPSR1MAPT | |
| SCHEMBL13823284 | 0.85 | CYP2C9 (0.74) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| Ticrynafen SCHEMBL11488956 | 0.85 | CYP2C9 (0.72) | CYP2C9ALDH1A1LMNANPSR1MAPT | |
| Ticrynafen SCHEMBL11488959 | 0.85 | CYP2C9 (0.72) | CYP2C9ALDH1A1LMNANPSR1MAPT | |
| SCHEMBL11358124 | 0.84 | CYP2C9 (0.72) | CYP2C9ALDH1A1LMNANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3354 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250057876-A1 | METHODS FOR TREATING AND/OR PREVENTING LYMPHANGIOGENESIS-ASSOCIATED DISEASES BY USING GOLD NANOCLUSTERS | GOLDRED NANOBIOTECH CO., LTD. (TW) | 2025-02-20 | — | — | US | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023225282-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| WO-2023137518-A1 | PLATINUM COMPLEXES | Western Sydney University (AU) | 2023-07-27 | — | — | WO | claimed |
| CN-116199267-A | Layered double hydroxide synthesized by high-iron magnesium acidic mine water and preparation method and application thereof | 中国科学院南京土壤研究所 | 2023-06-02 | — | — | CN | claimed |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-0011818-B1 | MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS BASED ON ALDOSTERONE ANTAGONISTS AND DIURETICS AND PROCESS FOR THEIR MANUFACTURE | CIBA-GEIGY AG (CH) | 1983-01-19 | — | — | EP | claimed |
| EP-0029740-A1 | Process for the preparation of a therapeutically active substituted phenoxyacetic acid and a novel acid anhydride for use therein | Farmos-Yhtyma Oy (FI) | 1981-06-03 | — | — | EP | claimed |
| US-4261985-A | REDUCED EXCRETION OF POTASSIUM IONS BY INCLUSION OF ALDOSTERONE ANTAGONIST | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | claimed |
| EP-0022330-A2 | Synergistic antihypertensive compositions | SMITHKLINE BECKMAN CORPORATION (US) | 1981-01-14 | — | — | EP | claimed |
| US-4239771-A | Water-soluble salts of tienilic acid | ALBERT ROLLAND S.A. (FR) | 1980-12-16 | — | — | US | claimed |
| US-4217347-A | MERCAPTOALKYL ALKANOYLPROLINES AND A DIURETIC | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | claimed |
| US-4166061-A | Use of cyclic esters to prepare 2,3-dichloro-4-(2-thenoyl)phenoxyacetic acid | SMITHKLINE CORPORATION (US) | 1979-08-28 | — | — | US | claimed |
| US-4107179-A | Method for preparing ticrynafen | SMITHKLINE CORPORATION (US) | 1978-08-15 | — | — | US | claimed |
| US-4089970-A | 4-(2-THENOYL)-2,3-DICHLOROPHENOXYACETIC ACID OR SALTS | SMITHKLINE CORPORATION (US) | 1978-05-16 | — | — | US | claimed |
| US-3969508-A | 4-(2-THENOYL)-2,3-DICHLORO-PHENOXYACETIC ACID | SMITHKLINE CORPORATION (US) | 1976-07-13 | — | — | US | claimed |